Guest: John Docherty <br>

  Host: Bruce Japsen <br>


  
    <p>While vaccines have emerged to treat a cancer caused by human papilloma virus, there is still a need for therapies to treat cancerous tissue caused by HPV. John Docherty, president of Toronto-based Helix BioPharma, tells host Bruce Japsen about his company's research and that of the biotech industry in the study and treatment of HPV, a key virus in the development of cervical cancer.</p>

Guest: John Docherty Host: Bruce Japsen While vaccines have emerged to treat a cancer caused by human papilloma virus, there is still a need for therapies to treat cancerous tissue caused by HPV. John Docherty, president of Toronto-based Helix BioPharma, tells host Bruce Japsen about his company's research and that of the biotech industry in the study and treatment of HPV, a key virus in the development of cervical cancer.

Potential Future Treatments for Human Papilloma Virus (HPV)

According to the American Cancer Society, yearly deaths from cancer are decreasing— marking the first period of decline in nearly 70 years. ReachMD takes a closer look at the driving forces behind these advances: medications that hone in on specific tumor targets, more accurate screening and diagnostic technologies, and pioneering surgical methods that provide new hope for patients suffering from these devastating diseases.

Share Potential Future Treatments for Human Papilloma Virus (HPV)

Sign up to save your podcasts

Potential Future Treatments for Human Papilloma Virus (HPV)

Potential Future Treatments for Human Papilloma Virus (HPV)